Disk diffusion test and E-test with enriched Mueller-Hinton agar for determining susceptibility of Candida species to voriconazole and fluconazole

Journal of Microbiology, Immunology and Infection

Volumn 42, Issue 2, 2009, Pages 148-153

  Lee, Sai Cheong ^a,b   Lo, Hsiu Jung ^c   Fung, Chang Phone ^d,e   Lee, Ning ^a   See, Lai Chu ^f  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Bacterial; Candida; Drug resistance; Fluconazole; Voriconazole

Indexed keywords

AGAR; FLUCONAZOLE; GLUCOSE; METHYLENE BLUE; VORICONAZOLE;

ANTIFUNGAL MACRODILUTION SUSCEPTIBILITY TEST; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BACTERIUM ISOLATE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA GUILLIERMONDII; CANDIDA PARAPSILOSIS; CANDIDA SAKE; CANDIDA TROPICALIS; CANDIDA UTILIS; CONTROLLED STUDY; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISK DIFFUSION; EPSILOMETER TEST; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREDICTION; SCREENING TEST;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CULTURE MEDIA; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TAIWAN; TRIAZOLES;

EID: 67651093959     PISSN: 16841182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Karlowsky JA, Zhanel GG, Klym KA, Hoban PJ, Kabani AM. Candidemia in a Canadian tertiary care hospital from 1976 to 1996. Diagn Microbiol Infect Dis. 1997;28:5-9.
2. Anaissie EJ, Rex JH, Uzun O, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med. 1998;104:238-245 (Pubitemid 28163168)
3. Nolla-Salas J, Sitges-Serra A, Leon-Gil C, Martinez-Gonzalez J, Leon-Regidor MA, Ibanez-Lucia P, et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Intensive Care Med. 1997;23:23-30. (Pubitemid 27067892)
4. Rex JH, Bennett JE, Sugar AM, Paphas PG, Serody J, Edwards JE, et al. Intravascular catheter exchange and duration of candidemia. Clin Infect Dis. 1995;21:994-996
5. Dean DA, Burchard KW. Surgical perspective on invasive Candida infections. World J Surg. 1998;22:127-134
6. Solomkin JS. Timing of treatment for nonneutropenic patients colonized with Candida. Am J Surg. 1996;172:445-475
7. Joly V, Carbon C. Editorial response: unfortunate in vitro selection of resistant Candida albicans with severe clinical consequences. Clin Infect Dis. 1998;27:692-694
8. Nguyen MH, Peacock JE, Morris AJ, Tanner DC, Nguyen ML, Snydman DR, et al. The changing face of candidemia, emergence of non-Candida albicans species and antifungal resistance. Am J Med. 1996;100:617-623
9. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. Wayne: National Committee for Clinical Laboratory Standards; 1997.
10. Colombo AL, Barchiesi F, McGough DA, Fothergill AW, Rinaldi MG. Evaluation of the E test system versus a microtitre broth method for antifungal susceptibility testing of yeasts against fluconazole and itraconazole. J Antimicrob Chemother. 1995;36:93-100.
11. Rodriguez-Tudela JL, Martinez-Suarez JV. Improved medium for fluconazole-susceptibility testing of Candida albicans. Antimicrob Agents Chemother. 1994;8:45-98.
12. Polanco AM, Rodriguez-Tudela JL, Baguer F, Sanchez-Sousa A, Martinez-Suarez JV. Improved method of determining the susceptibility of Candida albicans to fluconazole. J Antimicrob Chemother. 1995;35:155-159
13. Pfaller MA, Grant C, Morthland V, Rhine-Chalberg J. Comparative evaluation of alternative method for broth dilution susceptibilty testing of fluconazole against Candida albicans. J Clin Microbiol. 1994;32:506-509 (Pubitemid 24033921)
14. Pfaller MA, Dupont B, Kobayashi GS, Muller J, Rinaldi MG, Espinel-Ingroff A, et al. Standardized susceptibility testing of fluconazole: an international collaborative study. Antimicrob Agents Chemother. 1992;36:1805-1809
15. Barry AL, Brown SD. Fluconazole disk diffusion procedure for determining susceptibility of Candida species. J Clin Microbiol. 1996;34:2154-2157
16. Lee SC, Fung CP, Lee N, See LC, Huang JS, Tsai CJ, et al. Fluconazole disk diffusion test with methylene blue- and glucose-enriched Mueller-Hinton agar for determining susceptibility of Candida species. J Clin Microbiol. 2001;39:1615-1617 (Pubitemid 32275477)
17. Clinical and Laboratory Standards Institute. Method for antifungal disk diffusion susceptibility testing of yeasts. Proposed guideline. Wayne: National Committee for Clinical Laboratory Standards; 2004.
18. Pfaller MA, Bale M, Buschelman B, Lancaster M, Espinel-Ingroff A, Rex JH, et al. Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine. J Clin Microbiol. 1995;33:1104-1107
19. Duswald KH, Penk A, Pittrow L. High dose therapy with fluconazole. Mycoses. 1997;40:267-277
20. Jorgensen JH, Turnidge JD, Washington JA. Antibacterial susceptibility tests: dilution and disk diffusion methods. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of clinical microbiology. 7th ed. Washington: ASM Press; 1999:1526-1543